Forbion European Acquisition Corp.
FRBNU
NASDAQ Global Market20.00
USD
-0.62
- -
CIK
0001874495
CUSIP
G3619H128
Return %
Stock
S&P500
1Y
95.69
18.21
3Y
100.20
63.29
5Y
100.20
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jasper M. Bos
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 4001 Kennett Pike Wilmington DE United States of America 19807
- IPO Date
- Dec 10, 2021
- CIK
- 0001874495
- Website
- forbion.com
- Similar Companies
- Business
- Forbion European Acquisition Corp. (FRBNU) operates as a blank check company, or special purpose acquisition company (SPAC), sponsored by Forbion Growth Opportunities Fund I Cooperatief U.A., a life sciences venture capital firm; it pursues mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations, primarily targeting late-stage opportunities in the European life sciences and biotechnology sectors. Incorporated in 2021 and headquartered at 4001 Kennett Pike, Suite 302, Wilmington, Delaware, the company raised $110 million in its initial public offering in December 2021 at $10 per unit on Nasdaq, with units comprising one Class A ordinary share and one-third of a warrant exercisable at $11.50. FEAC integrates fully into Forbion's Growth Fund portfolio, leveraging the sponsor's resources, deal-sourcing expertise, and operational support from offices in Naarden, Netherlands; Munich, Germany; and Boston, Massachusetts, while focusing on human health innovations without conducting independent operations prior to a combination. In May 2023, FEAC announced a definitive business combination agreement with enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies via its dually derivatized chitosan (DDX) platform for mucosal tissue applications, backed by $135 million in committed financing including PIPE investments from Forbion Growth, BVF Partners, Omega Funds, Cowen Healthcare Investments, and others; the reverse merger closed on October 31, 2023, resulting in enGene Holdings Inc. (Nasdaq: ENGN) as the post-combination public entity with gross proceeds exceeding $138 million after redemptions, marking FEAC's status as realized in Forbion's portfolio. As of December 2025, FRBNU units continue trading on Nasdaq amid post-merger market activity for enGene Holdings, which maintains ongoing clinical development in gene therapy for conditions like bladder cancer and cystic fibrosis.